AUS
NZ
UK
CA
USA
IND
Highlights:
- 50% objective response rate in head and neck cancer patients, including a complete response
- 26% overall response rate across six solid tumor types
- New collaboration with Merck to combine PYX-201 with KEYTRUDA®
Pyxis Oncology (NASDAQ:PYXS) has announced promising preliminary results from its Phase 1 clinical trial of PYX-201, a novel antibody-drug conjugate (ADC) designed to target Extradomain-B Fibronectin, a protein that is overexpressed in various solid tumors. The data showcased significant clinical potential, particularly in patients with head and neck squamous cell carcinoma (HNSCC), as well as other solid tumor types.
In the trial, PYX-201 demonstrated a remarkable 50% objective response rate in HNSCC patients, including one complete response, offering hope for patients with limited treatment options. Furthermore, across six different solid tumor types, the drug achieved a 26% overall response rate, highlighting its broad potential for various cancers. The drug also showed an impressive 100% disease control rate (DCR) in HNSCC patients, reinforcing its therapeutic potential.
One of the key strengths of PYX-201 is its favorable safety profile, with a low incidence of treatment-related adverse events. This is a crucial factor for any cancer therapy, as many traditional treatments can cause significant side effects that limit their use. PYX-201’s manageable safety profile positions it as a promising option for patients who need effective treatments with fewer side effects.
Another notable aspect of PYX-201 is its enhanced stability in circulation compared to certain other approved ADCs, which is expected to improve the drug’s overall efficacy and reduce the potential for off-target effects. This feature further supports its potential as a next-generation cancer therapy.
In addition to these positive clinical trial results, Pyxis Oncology announced a new collaboration agreement with Merck to evaluate PYX-201 in combination with KEYTRUDA®, Merck’s highly successful PD-1 inhibitor. This partnership opens the door to potentially greater therapeutic efficacy, as combining targeted therapies like PYX-201 with immune checkpoint inhibitors like KEYTRUDA has shown promise in other cancer treatments. The first patient dosing in this combination trial is expected to begin in Q1 2025.
This collaboration with Merck marks a significant milestone for Pyxis Oncology, as it expands the clinical development of PYX-201 into combination therapy, potentially increasing its clinical value in the oncology space. The trial aims to evaluate whether the combination can provide synergistic benefits, enhancing the efficacy of both drugs in fighting cancer.
